Royalty Pharma Q4 2023 Earnings Report $31.58 -0.01 (-0.03%) As of 01/31/2025 04:00 PM Eastern Earnings HistoryForecast Royalty Pharma EPS ResultsActual EPS$1.15Consensus EPS $1.03Beat/MissBeat by +$0.12One Year Ago EPSN/ARoyalty Pharma Revenue ResultsActual Revenue$736.00 millionExpected Revenue$702.90 millionBeat/MissBeat by +$33.10 millionYoY Revenue GrowthN/ARoyalty Pharma Announcement DetailsQuarterQ4 2023Date2/15/2024TimeN/ARPRX Upcoming EarningsRoyalty Pharma will be holding an earnings conference call on Tuesday, February 11 at 8:30 AM Eastern. Interested parties can register for or listen to the call. Conference Call ResourcesSlide DeckPress ReleaseRPRX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Royalty Pharma Earnings HeadlinesRoyalty Pharma plc Closes $511 Million Monetization Transaction for MorphoSys Development Funding Bonds, Totaling $530 Million ProceedsJanuary 29 at 9:43 AM | quiverquant.comRoyalty Pharma Announces Sale of MorphoSys Development Funding BondsJanuary 29 at 9:00 AM | globenewswire.comIs this Elon’s true agenda?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors have all turned to my business partner and I for our thoughts on the market. And with every investor in America wondering what Elon is going to do now that he's in Washington, this is what we tell themFebruary 1, 2025 | Altimetry (Ad)Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025January 28, 2025 | globenewswire.comRoyalty Pharma’s Internalization and Promising Catalysts Lead to Buy Rating with Attractive ValuationJanuary 25, 2025 | markets.businessinsider.comWhy Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now?January 23, 2025 | msn.comSee More Royalty Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Royalty Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Royalty Pharma and other key companies, straight to your email. Email Address About Royalty PharmaRoyalty Pharma (NASDAQ:RPRX) operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.View Royalty Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings PayPal (2/3/2025)Palantir Technologies (2/3/2025)NXP Semiconductors (2/3/2025)Mitsubishi UFJ Financial Group (2/3/2025)Mondelez International (2/4/2025)Advanced Micro Devices (2/4/2025)Alphabet (2/4/2025)Alphabet (2/4/2025)Amgen (2/4/2025)Banco Bilbao Vizcaya Argentaria (2/4/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
